Osaka, Japan, July 23, 2012---Mitsubishi Tanabe Pharma Corporation (President and CEO: Michihiro Tsuchiya) announced today that the company would launch in July 24, 2012 DEPAS® TABLETS 0.25 mg, a new dosage formulation to be added to the series of tranquilizer being currently available under the brand names DEPAS® TABLETS 0.5 mg, DEPAS® TABLETS 1 mg (generic name: Japan Pharmacopoeia Etizolam Tablets), and DEPAS® FINE GRANULES 1% (generic name: Japan Pharmacopoeia Etizolam Fine Granules).

Since its launch in March 1984, DEPAS® has been one of the most commonly used anxiolytic agent in Japan. Due to its broad pharmacological properties and potent anxiolytic effect, sedative/hypnotic effect and relief from myotonia as well, DEPAS® shows reasonable effectiveness for psychosomatic disease, neurosis, low back pain, cervical spondylosis and tension headache, depression and sleep disorder.

Many elderly patients are treated by DEPAS®; there have been demands for a low-dose formulation that enables easy dose titration. DEPAS® TABLETS 0.25 mg meet these needs.

Mitsubishi Tanabe Pharma expects to contribute to improving quality of life for patients with anxiety through this launch of DEPAS® TABLETS 0.25 mg.